IDH1 and central nervous system cancer: Examples of such mutations include the succinate dehydrogenase mutation, linked to the development of paragangliomas [196], and the IDH mutations, commonly found in gliomas and serving as important diagnostic, prognostic, and predictive biomarkers for a favorable response to TMZ in glioma patients [10].